Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

Next Previous
Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydrocodone/paracetamol (Primary) ; VX 993 (Primary)
  • Indications Acute pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals

Most Recent Events

  • 04 Aug 2025 According to Vertex Pharmaceuticals media release, based on the results from this study, the company will not progress VX-993 into pivotal development as monotherapy in acute pain.
  • 04 Aug 2025 Primary endpoint (Time-weighted Sum of Pain Intensity Difference (SPID) as Recorded on the Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48)) has not been met.
  • 04 Aug 2025 Results presented in a Vertex Pharmaceuticals media.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top